erlotinib hydrochloride has been researched along with bafilomycin a1 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (bafilomycin a1) | Trials (bafilomycin a1) | Recent Studies (post-2010) (bafilomycin a1) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,120 | 1 | 484 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | bafilomycin a1 (IC50) |
|---|---|---|---|
| P2X purinoceptor 3 | Homo sapiens (human) | 0.755 | |
| V-type proton ATPase subunit S1 | Homo sapiens (human) | 0.1 | |
| Vacuolar proton pump subunit B | Gallus gallus (chicken) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YH; Hong, SE; Hong, SI; Hong, YJ; Jin, HO; Kim, B; Kim, CS; Kim, JH; Kim, JY; Lee, JK; Park, IC; Park, JA | 1 |
1 other study(ies) available for erlotinib hydrochloride and bafilomycin a1
| Article | Year |
|---|---|
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Lung Neoplasms; Macrolides; Membrane Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA Interference; Transfection; Vacuolar Proton-Translocating ATPases | 2015 |